Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress
03 Março 2022 - 11:41AM
Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company
committed to discovering and delivering the next generation of
precision cancer medicines, today announced the presentation of an
e-Poster at the 2022 European Society for Medical Oncology (ESMO)
Targeted Anticancer Therapies Congress, which is being held
virtually from March 7 – 8, 2022.
Details on Tango’s presentation at the 2022 ESMO
Targeted Anticancer Therapies Congress are as follows:
Poster Title: Evidence for synergy between
TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an
MTAPnull/KRASG12C xenograft modelAbstract
#: 24PDate and Time: Friday, March
4, 12:00 CET
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to
discovering novel drug targets and delivering the next generation
of precision medicine for the treatment of cancer. Using an
approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Forward-Looking Statements
Certain statements in this press release and the poster
referenced herein may be considered forward-looking statements.
Forward-looking statements generally relate to future events,
Tango’s future operating performance, goals, the anticipated
benefits of combination therapies (that include a Tango pipeline
product) expectations, beliefs and development objectives for
Tango’s product pipeline. In some cases, you can identify
forward-looking statements by terminology such as “may”, “should”,
“expect”, “intend”, “will”, “goal”, “estimate”, “anticipate”,
“believe”, “predict”, “potential” or “continue”, or the negatives
of these terms or variations of them or similar terminology. For
example, statements concerning the following include or constitute
forward-looking statements: that treatment of KRASG12C-mutant lung
adenocarcinoma with TNG908 and a KRASG12C inhibitor may be of
clinical benefit for certain patients; Tango’s ability to identify,
develop and commercialize drug candidates; the future anticipated
benefits of product candidates (including TNG908) and combination
therapies; and the expected timing of: (i) development candidate
declaration for certain targets, (ii) initiating IND-enabling
studies; (iii) filing INDs and (iv) clinical trial initiation. Such
forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially
from those expressed or implied by such forward looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by Tango and its
management are inherently uncertain. New risks and uncertainties
may emerge from time to time, and it is not possible to predict all
risks and uncertainties. Factors that may cause actual results to
differ materially from current expectations include, but are not
limited to: the benefits of Tango pipeline products and potential
combination therapies that are seen in pre-clinical experiments may
not be present in clinical trials or in use commercially or may not
be safe and/or effective in humans (and Tango or a third-party may
not be able to obtain approval or commercial sales of any
combination therapies); Tango may be unable to reach an agreement
with any third-party to evaluate and/or commercialize a Tango
product as a combination therapy with such third-party’s product;
Tango has a limited operating history and has not generated any
revenue to date from drug sales, and may never become profitable;
Tango will need to raise capital in the future and if we are unable
to raise capital when needed or on attractive terms, we would be
forced to delay, scale back or discontinue some of our development
programs or future commercialization efforts; we may be unable to
advance our preclinical development programs into and through the
clinic for safety or efficacy reasons or commercialize our product
candidates or we may experience significant delays in doing so as a
result of factors beyond Tango’s control; Tango’s approach to the
discovery and development of product candidates is novel and
unproven, which makes it difficult to predict the time, cost of
development, and likelihood of successfully developing any
products; Tango may not identify or discover additional product
candidates or may expend limited resources to pursue a particular
product candidate or indication and fail to capitalize on product
candidates or indications that may be more profitable or for which
there is a greater likelihood of success; our products candidates,
as a stand alone therapy or in combination with other therapies,
may cause adverse or other undesirable side effects that could,
among other things, delay or prevent regulatory approval; our
dependence on third parties for conducting clinical trials and
producing drug product; our ability to obtain and maintain patent
and other intellectual property protection for our technology and
product candidates or the scope of intellectual property protection
obtained is not sufficiently broad; and delays and other impacts on
product development and clinical trials from the COVID-19 pandemic.
Additional information concerning risks, uncertainties and
assumptions can be found in Tango’s filings with the SEC,
including the risk factors referenced in Tango’s Quarterly Report
on Form 10-Q filed with the SEC on November 9, 2021. You should not
place undue reliance on forward-looking statements in this
presentation, which speak only as of the date they are made and are
qualified in their entirety by reference to the cautionary
statements herein. Tango specifically disclaims any duty to update
these forward-looking statements.
Investor Contact:Sam Martin/Michael BarronArgot
Partnerstango@argotpartners.com
Media Contact:Joshua R. Mansbach Argot Partners
tango@argotpartners.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024